{"entity":{"id":"nct06787183","kind":"trial","name":"SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases","aka":[],"tldr":"A phase 2 trial of capecitabine, fOLFOX (5-FU, leucovorin, oxaliplatin) and QL1706 in colorectal cancer, run by Fujian Cancer Hospital, now recruiting.","summary":"SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases is a phase 2, interventional study registered as NCT06787183 by Fujian Cancer Hospital, with a registry enrolment figure of 42 participants, started 2025-12-01 and due to reach its primary completion in 2026-12-01. Interventions recorded: Short course radiotherapy; Capecitabine; Oxaliplatin; QL1706. Conditions listed: Locally Advanced Rectal Cancer With Liver Metastases. Primary outcome: Progression-free-Survival. Colorectal eligibility wording from the registry: \"Pathologically confirmed rectal cancer with liver metastases (stage M1)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06787183","url":"https://clinicaltrials.gov/study/NCT06787183"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt","platinum"],"targets":[],"drugs":["capecitabine","folfox","ql1706"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06787183","phase":"2","setting":"A Phase II Multicenter Clinical Trail of Efficacy and Safety of Short Course Radiotherapy Combined With CAPOX and PD-1/CTLA-4 Bispecific Antibody QL1706 in Patients With Liver Metastases From Rectal Cancer","sponsor":"Fujian Cancer Hospital","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06787183/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"ql1706","kind":"drug","name":"QL1706","route":"/drugs/ql1706/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}